Join Dr. Moul and Dr. Morris, 2 tenured researchers and clinicians in the field of prostate cancer, as they discuss apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer. Through discussion of patient case studies, this webinar will highlight key data from the Phase 3 TITAN study and review the efficacy and safety data of apalutamide with ADT. Dr.'s Moul and Morris will also delve into subpopulation analyses and prostate-specific antigen kinetics from the TITAN study.

This webinar is sponsored by Janssen and is not a certified medical education program.